J&J touts Tremfya win in Humira-resistant psoriatic arthritis patients amid showdown...

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Jun 3, 2021 at 11:02 PM.

  1. #1 cafead, Jun 3, 2021 at 11:02 PM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    33,024
    Likes Received:
    3
    via Johnson & Johnson’s Tremfya is relatively new to the psoriatic arthritis race, where multiple players are vying for market share. Facing a new high-profile in-class rival from AbbVie, the New Jersey pharma is building its case against older agents.

    article source
     
    Quote

Reply to Thread